Clik here to view.
ANR 2010: MIBG avidity, tandem transplant (Korea), and ch14.18 (Germany) updates
MIBG non-avid at diagnosis = better outcome? POC39 (p. 211) Neuroblastomas with non-avid I-123 MIBG scan and negative urinary catecholamine secretion: A single institute’s experience PL30 (p. 102)...
View ArticleCNCF 2010 ~ Dr Peter Zage on 3F8 phase II randomized trial
Dr Peter Zage from MD Anderson in Houston TX gave a presentation at the Children’s Neuroblastoma Cancer Foundation (CNCF) conference Saturday July 10, 2010 on the 3F8 randomized trial: A Study of...
View ArticleANR 2010 ~ Late Effects of Neuroblastoma Treatment
C10 (p. 80) “Late effects in neuroblastoma” Dr Lisa Diller (Boston Children’s/Dana-Farber Cancer Institute) reviewed recent published data on late effects and presented new data in the Neuroblastoma...
View ArticleClik here to view.
Latest neuroblastoma related news
Neuroblastoma bits from November 2010 . Excellent new review article on anti-GD2 antibodies Just published by Yang and Sondel, this thorough review tracks the evolution of antibodies for neuroblastoma...
View ArticleTwo years of cis-retinoic acid
A new trial opens: prolonged use of isotretinoin Aflac ST1001 Prolonged Isotretinoin Dr Howard Katzenstein at Emory University (Aflac) in Atlanta Georgia is the principal investigator of a...
View ArticleAACR 2011 ~ 102nd meeting
The American Association for Cancer Research (AACR) is the oldest and largest scientific organization in the world focused on every facet of cancer research. AACR was founded in 1907 by 11 physicians...
View ArticleThe Dosing of 13-Cis-Retinoic Acid (Accutane) in Neuroblastoma Therapy
The use of isotretinoin (13-cisRA, Accutane) is one part of a protocol used for the treatment of high-risk neuroblastoma (1). As many neuroblastoma families and patients know, taking this medication...
View Article
